Contact Information: Contact Information: Dr. Sandra Gilbert Clinical Research Coordinator 212-330-8532 sgilbert@daxor.com Stephen Feldschuh Chief Operating Officer 212-330-8500 stephen@daxor.com Diane Meegan Investor Relations 212-330-8512 dmeegan@daxor.com
Presentation of Five Research Reports Involving Daxor's Blood Volume Analyzer at the 39th Annual Society of Critical Care Medicine Conference. Part 2: Direct Blood Volume Measurement Correlated With Improved Survival
| Source: Daxor Corp.
NEW YORK, NY--(Marketwire - February 4, 2010) - Daxor Corporation (NYSE Amex : DXR ), a medical
instrumentation and biotechnology company, today announced that five
research reports were presented at the annual Society of Critical Care
Medicine (SCCM) conference in Miami, FL which involved the Daxor Blood
Volume Analyzer (BVA-100). The BVA-100 enables measurement of whole blood
volume, including plasma volume and red blood cell volume. The Principal
Investigators for these studies were Mihae Yu, MD, and Danny Takanishi Jr.,
MD, from the University of Hawaii, The Queen's Medical Center. Abstracts
which describe their findings were published in the December 2009
Supplement (Volume 37, Number 12) of the Critical Care Medicine journal.
These presentations are now available on Daxor's website at
www.daxor.com/sccm2010.asp.
Three of these studies focused on whether several commonly used surrogate
measures of blood volume status are in fact accurate predictors of blood
volume. One of the studies, entitled "A Prospective Randomized Trial Using
Blood Volume Analysis vs. Pulmonary Artery Catheter (PAC) Measurements to
Guide Fluid and Red Cell Management," examined whether using blood volume
data in addition to PAC data to guide resuscitation led to improved
outcomes. 100 critically ill surgical patients were randomized into either
of two treatment arms: resuscitation decisions in the blood volume group
were based on both the blood volume as well as the PAC findings. In
contrast, resuscitation decisions in the control group were based on PAC
measurements alone. The results showed that use of blood volume
measurement, in addition to PAC monitoring, allowed more precise
quantitation of patients' needs for fluids and red blood cells. This
ultimately resulted in a significant improvement in mortality in patients
for whom therapy was guided by both blood volume analysis and PAC (8%
mortality) vs. PAC alone (24% mortality).
Another study, entitled "A Comparison of Pulse Pressure and Blood Volume
Measurement," examined whether there was a correlation between pulse
pressure -- a surrogate marker of cardiac fluid responsiveness to fluid
infusion -- and intravascular blood volume. Simultaneous measurement of
pulse pressure and blood volume in 100 critically ill surgical patients
showed that there is no relationship between these two variables.
The third study, entitled "The Relationship Between Inferior Vena Cava
(IVC) Collapsibility Ratio and Measured Whole Blood Volume in Surgical
Critical Care Patients," examined the correlation between IVC and blood
volume. Collapsibility of the IVC is calculated as the difference between
the maximum and minimum diameters of the IVC throughout the respiratory
cycle. IVC is sometimes used as an estimate of central venous pressure --
which is an imperfect correlate for blood volume -- in critically ill
patients. However, retrospective examination of data collected from 43
surgical critical care patients showed no relationship between IVC and
blood volume.
These studies are extremely important as they demonstrate that three
commonly used markers for critical care patient resuscitation status (Pulse
pressure, IVC and PAC) do not provide accurate estimates of patients' blood
volumes. Blood volume data is an extremely important factor in optimizing
resuscitation of critically ill patients, and this information can be
accurately obtained only by direct measurement of intravascular blood
volume. Physicians who continue to rely on imprecise surrogate measures of
volume status may under- or overtransfuse their patients with fluids and
red blood cells, thereby doing harm to the patients they are trying to
help. A fundamental goal of Daxor Corporation is to make direct blood
volume measurement the standard of care in the treatment of critically ill
patients in the intensive care unit.
The following investigators were involved in these studies: Mihae Yu, MD,
Danny Takanishi, Jr., MD, Shirley Domingo, MD, Marc Osborne, MD, Sharon
Moran, MD, Kevin Pei, MD, Kurt Edwards, MD, Sharon Takiguchi, MD, Susan
Steinemann, MD, Maimona Ghows, MD, Andrew Tan, MD, and Fedor Lurie, MD.
Further details about this research are available on Daxor's website.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
www.Daxor.com.